Actively Recruiting
Personalized Immunotherapy Treatment for Early-Stage Unfavorable Classical Hodgkin Lymphoma Phase II Study Using Tislelizumab With or Without Chemotherapy
Led by University of Cologne · Updated on 2024-07-26
120
Participants Needed
1
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating an individualized first-line immunotherapy treatment for early-stage unfavorable classical Hodgkin lymphoma cHL. This phase II trial aims to find a treatment approach that is effective and better tolerated, especially by reducing the need for standard chemo- or radiotherapy, which can cause short- and long-term side effects. The study is designed to offer a chemo- and radiotherapy-free option to patients who respond well early on to treatment with PD-1 checkpoint inhibition. Participants aged 18 to 60 will receive two initial doses of the drug tislelizumab every 21 days, followed by an interim PET scan after these doses. Based on their PET scan results, those with a negative scan continue with additional doses of tislelizumab every 28 days. Those with a positive scan receive combined treatment with tislelizumab and AVD chemotherapy in 28-day cycles, followed by radiotherapy only if the PET scan remains positive after treatment. Patients over 60 will be treated in a separate group, receiving a similar PET-guided approach with tislelizumab or combined therapy, but all will receive radiotherapy after treatment. During the study, participants will undergo PET scans to guide treatment decisions and monitoring. The main outcome measured is progression-free survival at one year. Safety and treatment response will be followed carefully, with radiotherapy reserved for cases where residual disease is detected by PET scans after immunotherapy or combination therapy. The total duration and follow-up details are aligned with the treatment cycles and imaging assessments throughout the trial period.
CONDITIONS
Brief Title
Phase II Trial of Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
Research Team
M
Michael Fuchs
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here